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Introduction
Induction of phase-I enzymes by microsomal enzyme inducers (MEIs) can be attributed to activation of signal-transduction pathways. Many MEIs exert their effects through activation of various orphan nuclear receptors, subsequently enhancing target gene transcription (Sonoda et al., 2003; Denison et al., 2003) . For example, TCDD binds to the aryl hydrocarbon receptor (AhR), which subsequently releases the AhR from the cytosolic tethering protein HSP90, allowing for AhR translocation to the nucleus, heterodimerization with ARNT, and binding to xenobiotic response elements in the Cyp1A1 promoter. Similarly, constitutive androstane receptor (CAR) ligands induce Cyp2B10, pregnane-X receptor (PXR) ligands induce Cyp3A11, and peroxisome proliferator-activated receptor α (PPARα) ligands induce Cyp4A14. The NF-E2 related factor 2 (Nrf2) pathway is more complex, where both antioxidants and oxidants can either alter the tethering protein Keap1 by sulfhydryl modifications, or alter the cellular oxidative state in such a way to allow Nrf2 to be released, allowing for subsequent translocation of Nrf2 to the nucleus, heterodimerization with small Maf proteins, and binding to EpRE/ARE in the promoter regions of genes, such as NAD(P)H quinone oxidoreductase 1 (Nqo1) (Jaiswal et al., 2000) .
Examples of receptor-mediated regulation of Oatp transporters have also been reported in the literature, such as the induction of Oatp1a4, via PXR activation and subsequent binding to the 5´-flanking region of the rat Oatp1a4 gene (Guo et al., 2002b) . Similar observations in wildtype mice, but not in PXR-null mice have also been reported Sonoda et al., 2002) . Other observations, such as the decrease in Oatp1a4 expression in rats after treatment with the AhR ligand polychlorinated biphenyl (PCB)126, suggest a receptormediated mechanism (Guo et al., 2002a) . This article has not been copyedited and formatted. The final version may differ from this version. Hepatic uptake must occur for some chemicals prior to undergoing biotransformation.
Oatp uptake transporters function as an important part of the "first-pass" extraction of chemicals from systemic circulation into liver. Therefore, the potential for co-regulation of drug metabolizing enzymes and transporters exists because uptake and biotransformation of drugs could theoretically occur by a coordinated receptor activation mechanism. One such example exists with the PXR ligand pregnenolone-16α-carbonitrile (PCN), which markedly enhances both plasma disappearance and biliary excretion of cardiac glycosides in rats (Klaassen, 1974) . Recently, the uptake transporter Oatp1a4, which transports cardiac glycosides with high affinity (Noé et al., 1997) , has been shown to be induced by PCN in rats (Rausch-Derra et al., 2001; Guo et al., 2002) . Cardiac glycosides are taken up into the liver by Oatp1a4 in rodents, biotransformed by Cyp3A and UDP-glucuronosyltransferases (UGTs), and excreted into bile via the canalicular transporter Mdr1. Activation of PXR by PCN leads to coordinate induction of Oatp1a4, Cyp3A, and UGTs, as well as biliary excretion of cardiac glycosides (Klaassen, 1974; Rausch-Derra et al., 2001; Guo et al., 2002; Chen et al., 2003) .
Another example of coordinate regulation of transporters and drug metabolizing enzymes is with phenobarbital (PB), a constitutive androstane receptor (CAR) activator. PB increases the plasma clearance of the Oatp substrate bilirubin (Klaassen, 1970) , thus implicating an uptake transporter, and furthermore induces bilirubin UDP-glucuronosyltransferase UGT1A1 in liver (Ritter et al., 1999) .
There is limited information linking Oatp transporter regulation with phase-I enzymes via transcription factor activation. Therefore, we hypothesize that the expression of drugmetabolizing enzymes and Oatps might be coordinately regulated in liver. In the present study, we investigate the effect of MEIs with known mechanisms of induction on mouse Oatp This article has not been copyedited and formatted. The final version may differ from this version. oil by po, saline by ip, and saline by po) were used. No statistical difference between these groups was observed, thus these groups were averaged together as a single vehicle control group. All injections were administered in a volume of 10 ml/kg. Livers were removed on day 5, snap-frozen in liquid nitrogen, and stored at -80°C.
This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Effects of the Prototypical Microsomal Enzyme Inducers on the mRNA Levels of Mouse Biotransformation Enzymes.
Male C57BL/6 mice were dosed with five classes of prototypical drug-metabolizing enzyme inducers. Each class contains three chemicals that are known to transcriptionally activate a specific signaling pathway. The doses were chosen according to what is commonly cited in the literature to activate specific transcription factors that target specific biotransformation enzymes (Cyp1A1, Cyp2B10, Cyp3A11, Cyp4A14, and Nqo1). To confirm that the doses selected were effective, the mRNA levels of these marker genes were quantified ( Oatp1a4 is a sinusoidal uptake transporter that is known for transporting digoxin with high affinity (Noé et al, 1997) . Mouse Oatp1a4 is up-regulated by PCN treatment , which was also observed in the present study. Another PXR ligand, spironolactone, induced Oatp1a4 mRNA expression approximately two fold. The Nrf2 activator BHA also induced Oatp1a4 mRNA about two fold. Otherwise, Oatp1a4 mRNA was not significantly altered by treatment with any of the AhR, CAR, or PPARα activators (Fig. 2) .
Regulation of Oatp1a5 in liver by classes of microsomal enzyme inducers is shown in Fig. 2 . The expression of Oatp1a5 is minimal in liver, which has been reported previously (Choudhuri et al., 2003) . The majority of CAR and PXR ligands decreased Oatp1a5 mRNA levels.
Like Oatp1a5, Oatp1a6 is minimally expressed in liver. Regulation of Oatp1a6 by the microsomal enzyme inducers is shown in Fig. 2 . There was no significant alteration of This article has not been copyedited and formatted. The final version may differ from this version. Regulation of Oatp1c1, which is minimally expressed in liver, by the 5 classes of transcription factor activators, is shown in Fig. 3 . None of the five classes of chemicals altered Oatp1c1 expression.
Chemical regulation of Oatp2a1, a prostaglandin transporter, is shown in Fig. 3 . Both PXR and PPARα ligands caused a class-wide decrease in Oatp2a1 mRNA expression.
Furthermore, an AhR ligand, BNF, and an Nrf2 activator, BHA, increased Oatp2a1 mRNA expression, but other AhR and Nrf2 activators did not alter Oatp2a1 mRNA expression.
Oatp2b1 is also a liver-predominant Oatp. As shown in Fig. 4 , expression of Oatp2b1 was decreased by PXR and PPARα ligands, and increased by AhR and Nrf2 activators. Two CAR activators, PB and DAS, decreased Oatp2b1 mRNA expression. However, TCPOBOP, a third CAR activator, increased Oatp2b1 mRNA expression.
Oatp3a1 and 4a1 are minimally expressed in liver. Regulation of these two transporters by the five classes of transcription factor activators is shown in Fig. 4 . All AhR ligands increased Oatp3a1 mRNA expression, whereas PXR ligands decreased Oatp3a1 mRNA expression. As also shown in Fig. 4 
Discussion
Virtually all chemicals were once believed to enter the liver through passive diffusion;
however, an emerging role for the Oatp family in hepatic uptake suggests a more important role for transporters than once believed. In vivo, uptake transporters such as OATPs/Oatps are necessary for some chemicals to cross the membrane in order to access phase-I and -II enzymes. However, in vitro assays such as microsomal preparations allow for direct access of a substrate to these microsomal enzymes. Therefore, regulation of uptake transport by microsomal enzyme inducers may lead to increased availability of drugs and chemicals for metabolism. Therefore, integration of the regulation of the four processes (uptake, phase-I metabolism, phase-II metabolism, and efflux) may increase the efficacy of detoxication. This study examines the potential of transcription factors that activate phase-I drug metabolism to also affect the regulation of Oatp hepatic uptake transporters.
Phase-I drug metabolizing enzymes often have low expression in naïve liver, but can be induced tens to hundreds of fold after exposure to chemicals that activate specific transcription factors. Except for Cyp3A11, the basal expression of phase-I enzymes examined in this study (Cyp1A1, Cyp2B10, Cyp4A14, and Nqo1) is very low in liver. However, AhR ligands (TCDD, BNF, and PCB126) induced Cyp1A1 over 1,000 fold, CAR activators produced 20-times more Cyp2B10 mRNA, and PPARα ligands increased Cyp4A14 mRNA 120 fold (Fig 1) . The most robust up-regulation of these cytochrome P-450s, such as the induction of Cyp1a1 after TCDD exposure, has been extensively examined (Jaiswal et al, 1985; Jones et al. 1986 can evoke a similar increase in Cyp3A4 via PXR activation, whereas in rodents, Cyp3A11 is up-regulated by chemicals such as PCN and DEX (Lehmann et al, 1998; ). However, the expression of Cyp3A4 can also be markedly increased after treatment with PB or DEX (Fig 1) (Burk et al., 2004; Zhang et al., 2004) . Known up-regulation of suggest a novel mechanism of Cyp3A11 regulation (Fig 1) . Overlap of Nrf2/AhR activators has been observed previously for other phase-I and II enzymes, including UGT1A6 by oltipraz, and induction of Nqo1 by TCDD (Auyeung et al, 2003; Ma et al, 2004) . It has been suggested that oxidative stress can induce CYP3A4 expression in the human erythroleukemia cell line K562 (Negai et al, 2004) . The protective role of Nrf2 in oxidative stress has been well established, and these results, when taken together, may suggest a role for Nrf2 in regulation of Cyp3A11.
Another novel observation from this study is that TCPOBOP, an efficacious CAR activator, and DAS, a garlic component, up-regulate Nqo1 mRNA expression (Fig 1) . The mechanism of TCPOBOP and DAS induction of Nqo1 is not known, but it could be due to generation of reactive oxidants by the increased amount of Cyp2B. A precedent for this This article has not been copyedited and formatted. The final version may differ from this version. (Ma et al., 2004) . Nqo1 induction is thought to be a result of increased Cyp1A1 activity, which leads to an increased production of oxidative metabolites. These reactive species activate Nrf2, which ultimately up-regulate PPARα activators also decreased Oatp1a1, 1a6, 1b2, 2a1, and 2b1 mRNA expression (Fig 2, 3 , and 4). Finally, the majority of Nrf2 activators decreased Oatp1a1 mRNA expression (Fig 2) , whereas, only Oatp2b1 was increased by Nrf2 class of activators (Fig 4) .
Increased uptake and biotransformation can either enhance the elimination and detoxication, or enhance the hepatotoxicity of chemicals (Nozawa et al., 2004) . For example microcystin and phalloidin, two Oatp substrates, cause hepatotoxicity after accumulating in the liver (Hagenbuch and Meier, 2003) . Conversely, pretreatment of rats with PCN or SPR (PXR ligands) decreases the toxicity of digoxin by increasing hepatic uptake and biotransformation, via PXR activation and subsequent up-regulation of Oatp1a4 and Cyp3A11. Similarly, induction of Oatp1A4 and Cyp3A11, and down-regulation of Cyp7A1 have been observed after PXR activation by lithocholic acid. This mechanism is believed to occur as a feedback pathway to protect the liver from bile acid toxicity by decreasing bile acid synthesis, and increasing uptake and metabolism of hydrophobic bile acids by increasing Oatp1a4 and Cyp3A11 levels ).
In summary, the present study examines expression of some phase-I enzymes known to livers was analyzed by the bDNA assay. All data were expressed as mean ± S.E. for five animals in each group, except for control groups, which were combined from the four individual control groups after it was determined that they were not statistically different.
Asterisk indicates statistically significant difference between treated and control mice (p<0.05).
Fig. 2
Expression of Oatp1a1, 1a4, 1a5, and 1a6 mRNA in liver after treatment with prototypical drug-metabolizing enzyme inducers. The abbreviations used are the same as in Fig. 1 . Total RNA from liver of chemically treated male C57BL/6 mice (n = 5/treatment) was analyzed by the bDNA assay. All data were expressed as mean ± S.E. for five animals in each group, except for control groups, which were combined from the four individual control groups after it was determined that they were not statistically different. Asterisk indicates statistically significant difference between treated and control mice (p<0.05). 5/treatment) was analyzed by the bDNA assay. All data were expressed as mean ± S.E. for five animals in each group, except for control groups, which were combined from the four individual control groups after it was determined that they were not statistically different.
Fig. 4
Expression of Oatp2b1 (top), 3a1 (middle), and 4a1 (bottom) mRNA in liver after treatment with prototypical drug-metabolizing enzyme inducers. The abbreviations used are the same as in Fig. 1 . Total RNA from liver of chemically treated male C57BL/6 mice (n = 5/treatment) was analyzed by the bDNA assay. All data were expressed as mean ± S.E. for five animals in each group, except for control groups, which were combined from the four individual control groups after it was determined that they were not statistically different.
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